- call +1-201-465-4211
- email sales@mrinsights.biz
Conjugate vaccines are formed by covalently bonding a weak antigen to the strong antigen. It boosts the hosts’ immune response. Conjugate vaccines are germ specific and can identify targeted germ only, so it can be used as a preventative measure to provide additional protection. Conjugate vaccines are used to treat Hib (Haemophilus influenzae type b) disease, Hepatitis B, HPV (Human papillomavirus), Whooping cough (part of the DTaP combined vaccine), Pneumococcal disease, Meningococcal disease, and Shingles.
Scope of the Report:
This report focuses on the Conjugate Vaccine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The rising occurrence of diseases caused by microorganisms, increasing awareness about prevention of infectious diseases, and an increasing number of regulatory approvals to the vaccines are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by top players such as new product launches are contributing to the growth of the market.
The worldwide market for Conjugate Vaccine is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
GlaxoSmithKline
Pfizer
Merck
Sanofi Pasteur
CSL
Emergent BioSolutions
Johnson & Johnson
Medimmune
Astellas Pharma
Serum Institute of India
Bavarian Nordi
Mitsubishi Tanabe Pharma
Daiichi Sankyo Company
Fablife
SutroVax
Sinovac Biotech
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Monovalent
Multivalent
Market Segment by Applications, can be divided into
Hospitals
Clinics
There are 15 Chapters to deeply display the global Conjugate Vaccine market.
Chapter 1, to describe Conjugate Vaccine Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Conjugate Vaccine, with sales, revenue, and price of Conjugate Vaccine, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Conjugate Vaccine, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Conjugate Vaccine market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Conjugate Vaccine sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Conjugate Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Monovalent
1.2.2 Multivalent
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Clinics
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 GlaxoSmithKline
2.1.1 Business Overview
2.1.2 Conjugate Vaccine Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 GlaxoSmithKline Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Pfizer
2.2.1 Business Overview
2.2.2 Conjugate Vaccine Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Pfizer Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Merck
2.3.1 Business Overview
2.3.2 Conjugate Vaccine Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Merck Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Sanofi Pasteur
2.4.1 Business Overview
2.4.2 Conjugate Vaccine Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Sanofi Pasteur Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 CSL
2.5.1 Business Overview
2.5.2 Conjugate Vaccine Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 CSL Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Emergent BioSolutions
2.6.1 Business Overview
2.6.2 Conjugate Vaccine Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Emergent BioSolutions Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Johnson & Johnson
2.7.1 Business Overview
2.7.2 Conjugate Vaccine Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Johnson & Johnson Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Medimmune
2.8.1 Business Overview
2.8.2 Conjugate Vaccine Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Medimmune Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Astellas Pharma
2.9.1 Business Overview
2.9.2 Conjugate Vaccine Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Astellas Pharma Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Serum Institute of India
2.10.1 Business Overview
2.10.2 Conjugate Vaccine Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Serum Institute of India Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Bavarian Nordi
2.11.1 Business Overview
2.11.2 Conjugate Vaccine Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Bavarian Nordi Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Mitsubishi Tanabe Pharma
2.12.1 Business Overview
2.12.2 Conjugate Vaccine Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Mitsubishi Tanabe Pharma Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Daiichi Sankyo Company
2.13.1 Business Overview
2.13.2 Conjugate Vaccine Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Daiichi Sankyo Company Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 Fablife
2.14.1 Business Overview
2.14.2 Conjugate Vaccine Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Fablife Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 SutroVax
2.15.1 Business Overview
2.15.2 Conjugate Vaccine Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 SutroVax Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.16 Sinovac Biotech
2.16.1 Business Overview
2.16.2 Conjugate Vaccine Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Sinovac Biotech Conjugate Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Conjugate Vaccine Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Conjugate Vaccine Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Conjugate Vaccine Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Conjugate Vaccine Manufacturer Market Share in 2017
3.3.2 Top 6 Conjugate Vaccine Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Conjugate Vaccine Market Analysis by Regions
4.1 Global Conjugate Vaccine Sales, Revenue and Market Share by Regions
4.1.1 Global Conjugate Vaccine Sales and Market Share by Regions (2013-2018)
4.1.2 Global Conjugate Vaccine Revenue and Market Share by Regions (2013-2018)
4.2 North America Conjugate Vaccine Sales and Growth Rate (2013-2018)
4.3 Europe Conjugate Vaccine Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Conjugate Vaccine Sales and Growth Rate (2013-2018)
4.5 South America Conjugate Vaccine Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Conjugate Vaccine Sales and Growth Rate (2013-2018)
5 North America Conjugate Vaccine by Countries
5.1 North America Conjugate Vaccine Sales, Revenue and Market Share by Countries
5.1.1 North America Conjugate Vaccine Sales and Market Share by Countries (2013-2018)
5.1.2 North America Conjugate Vaccine Revenue and Market Share by Countries (2013-2018)
5.2 United States Conjugate Vaccine Sales and Growth Rate (2013-2018)
5.3 Canada Conjugate Vaccine Sales and Growth Rate (2013-2018)
5.4 Mexico Conjugate Vaccine Sales and Growth Rate (2013-2018)
6 Europe Conjugate Vaccine by Countries
6.1 Europe Conjugate Vaccine Sales, Revenue and Market Share by Countries
6.1.1 Europe Conjugate Vaccine Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Conjugate Vaccine Revenue and Market Share by Countries (2013-2018)
6.2 Germany Conjugate Vaccine Sales and Growth Rate (2013-2018)
6.3 UK Conjugate Vaccine Sales and Growth Rate (2013-2018)
6.4 France Conjugate Vaccine Sales and Growth Rate (2013-2018)
6.5 Russia Conjugate Vaccine Sales and Growth Rate (2013-2018)
6.6 Italy Conjugate Vaccine Sales and Growth Rate (2013-2018)
7 Asia-Pacific Conjugate Vaccine by Countries
7.1 Asia-Pacific Conjugate Vaccine Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Conjugate Vaccine Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Conjugate Vaccine Revenue and Market Share by Countries (2013-2018)
7.2 China Conjugate Vaccine Sales and Growth Rate (2013-2018)
7.3 Japan Conjugate Vaccine Sales and Growth Rate (2013-2018)
7.4 Korea Conjugate Vaccine Sales and Growth Rate (2013-2018)
7.5 India Conjugate Vaccine Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Conjugate Vaccine Sales and Growth Rate (2013-2018)
8 South America Conjugate Vaccine by Countries
8.1 South America Conjugate Vaccine Sales, Revenue and Market Share by Countries
8.1.1 South America Conjugate Vaccine Sales and Market Share by Countries (2013-2018)
8.1.2 South America Conjugate Vaccine Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Conjugate Vaccine Sales and Growth Rate (2013-2018)
8.3 Argentina Conjugate Vaccine Sales and Growth Rate (2013-2018)
8.4 Colombia Conjugate Vaccine Sales and Growth Rate (2013-2018)
9 Middle East and Africa Conjugate Vaccine by Countries
9.1 Middle East and Africa Conjugate Vaccine Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Conjugate Vaccine Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Conjugate Vaccine Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Conjugate Vaccine Sales and Growth Rate (2013-2018)
9.3 UAE Conjugate Vaccine Sales and Growth Rate (2013-2018)
9.4 Egypt Conjugate Vaccine Sales and Growth Rate (2013-2018)
9.5 Nigeria Conjugate Vaccine Sales and Growth Rate (2013-2018)
9.6 South Africa Conjugate Vaccine Sales and Growth Rate (2013-2018)
10 Global Conjugate Vaccine Market Segment by Type
10.1 Global Conjugate Vaccine Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Conjugate Vaccine Sales and Market Share by Type (2013-2018)
10.1.2 Global Conjugate Vaccine Revenue and Market Share by Type (2013-2018)
10.2 Monovalent Sales Growth and Price
10.2.1 Global Monovalent Sales Growth (2013-2018)
10.2.2 Global Monovalent Price (2013-2018)
10.3 Multivalent Sales Growth and Price
10.3.1 Global Multivalent Sales Growth (2013-2018)
10.3.2 Global Multivalent Price (2013-2018)
11 Global Conjugate Vaccine Market Segment by Application
11.1 Global Conjugate Vaccine Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Clinics Sales Growth (2013-2018)
12 Conjugate Vaccine Market Forecast (2018-2023)
12.1 Global Conjugate Vaccine Sales, Revenue and Growth Rate (2018-2023)
12.2 Conjugate Vaccine Market Forecast by Regions (2018-2023)
12.2.1 North America Conjugate Vaccine Market Forecast (2018-2023)
12.2.2 Europe Conjugate Vaccine Market Forecast (2018-2023)
12.2.3 Asia-Pacific Conjugate Vaccine Market Forecast (2018-2023)
12.2.4 South America Conjugate Vaccine Market Forecast (2018-2023)
12.2.5 Middle East and Africa Conjugate Vaccine Market Forecast (2018-2023)
12.3 Conjugate Vaccine Market Forecast by Type (2018-2023)
12.3.1 Global Conjugate Vaccine Sales Forecast by Type (2018-2023)
12.3.2 Global Conjugate Vaccine Market Share Forecast by Type (2018-2023)
12.4 Conjugate Vaccine Market Forecast by Application (2018-2023)
12.4.1 Global Conjugate Vaccine Sales Forecast by Application (2018-2023)
12.4.2 Global Conjugate Vaccine Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Conjugate Vaccine Picture
Table Product Specifications of Conjugate Vaccine
Figure Global Sales Market Share of Conjugate Vaccine by Types in 2017
Table
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
